Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Axitinib + Dalantercept
Indication/Tumor Type renal cell carcinoma
Response Type no benefit

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown renal cell carcinoma no benefit Axitinib + Dalantercept Phase II Actionable In a Phase II trial (DART), the combination of Dalantercept (ACE-041) and Inlyta (axitinib) did not significantly improve median progression-free survival (6.8 vs 5.6 months, HR=1.11, p=0.670), median overall survival (HR=1.39, p=0.349), or objective response rate (11/38, 19.0% vs 15/61, 24.6%) compared to placebo plus Inlyta (axitinib) in patients with advanced renal cell carcinoma (PMID: 30951193; NCT01727336). 30951193
PubMed Id Reference Title Details
(30951193) A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma. Full reference...